Waters Corporation
Waters Corporation WAT Peers
See (WAT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| WAT | $355.50 | +1.57% | 21.1B | 32.18 | $11.03 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.56% |
| TMO | $411.25 | +0.15% | 155.6B | 24.15 | $17.06 | +0.40% |
| DHR | $202.88 | +0.94% | 144.3B | 39.00 | $5.17 | +0.56% |
| IDXX | $529.44 | -0.18% | 42.5B | 48.84 | $10.81 | N/A |
| A | $119.88 | +1.06% | 33.9B | 29.42 | $4.06 | +0.81% |
| IQV | $158.06 | -0.41% | 27.4B | 21.58 | $7.33 | N/A |
| MTD | $1,199.40 | +0.55% | 24.8B | 29.81 | $40.04 | N/A |
| NTRA | $166.89 | +1.67% | 23B | -113.63 | -$1.48 | N/A |
| DGX | $177.07 | -0.88% | 19.8B | 22.38 | $7.91 | +1.74% |
Stock Comparison
WAT vs DHR-PB Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, WAT is priced at $355.50, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, WAT's ROE is +0.39%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, WAT is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs TMO Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, TMO has a market cap of 155.6B. Regarding current trading prices, WAT is priced at $355.50, while TMO trades at $411.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas TMO's P/E ratio is 24.15. In terms of profitability, WAT's ROE is +0.39%, compared to TMO's ROE of +0.13%. Regarding short-term risk, WAT is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs DHR Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, DHR has a market cap of 144.3B. Regarding current trading prices, WAT is priced at $355.50, while DHR trades at $202.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas DHR's P/E ratio is 39.00. In terms of profitability, WAT's ROE is +0.39%, compared to DHR's ROE of +0.07%. Regarding short-term risk, WAT is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs IDXX Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, IDXX has a market cap of 42.5B. Regarding current trading prices, WAT is priced at $355.50, while IDXX trades at $529.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas IDXX's P/E ratio is 48.84. In terms of profitability, WAT's ROE is +0.39%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, WAT is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs A Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, A has a market cap of 33.9B. Regarding current trading prices, WAT is priced at $355.50, while A trades at $119.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas A's P/E ratio is 29.42. In terms of profitability, WAT's ROE is +0.39%, compared to A's ROE of +0.19%. Regarding short-term risk, WAT is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs IQV Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, IQV has a market cap of 27.4B. Regarding current trading prices, WAT is priced at $355.50, while IQV trades at $158.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas IQV's P/E ratio is 21.58. In terms of profitability, WAT's ROE is +0.39%, compared to IQV's ROE of +0.21%. Regarding short-term risk, WAT is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs MTD Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, MTD has a market cap of 24.8B. Regarding current trading prices, WAT is priced at $355.50, while MTD trades at $1,199.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas MTD's P/E ratio is 29.81. In terms of profitability, WAT's ROE is +0.39%, compared to MTD's ROE of +1.21%. Regarding short-term risk, WAT is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs NTRA Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, NTRA has a market cap of 23B. Regarding current trading prices, WAT is priced at $355.50, while NTRA trades at $166.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas NTRA's P/E ratio is -113.63. In terms of profitability, WAT's ROE is +0.39%, compared to NTRA's ROE of -0.18%. Regarding short-term risk, WAT is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs DGX Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, DGX has a market cap of 19.8B. Regarding current trading prices, WAT is priced at $355.50, while DGX trades at $177.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas DGX's P/E ratio is 22.38. In terms of profitability, WAT's ROE is +0.39%, compared to DGX's ROE of +0.13%. Regarding short-term risk, WAT is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs ILMN Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, ILMN has a market cap of 14.9B. Regarding current trading prices, WAT is priced at $355.50, while ILMN trades at $94.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas ILMN's P/E ratio is -15.49. In terms of profitability, WAT's ROE is +0.39%, compared to ILMN's ROE of -0.46%. Regarding short-term risk, WAT is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs PKI Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, WAT is priced at $355.50, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas PKI's P/E ratio is 41.45. In terms of profitability, WAT's ROE is +0.39%, compared to PKI's ROE of +0.04%. Regarding short-term risk, WAT is less volatile compared to PKI. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs ICLR Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, ICLR has a market cap of 11.9B. Regarding current trading prices, WAT is priced at $355.50, while ICLR trades at $146.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas ICLR's P/E ratio is 15.99. In terms of profitability, WAT's ROE is +0.39%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, WAT and ICLR have similar daily volatility (1.52).
WAT vs RVTY Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, RVTY has a market cap of 11.6B. Regarding current trading prices, WAT is priced at $355.50, while RVTY trades at $98.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas RVTY's P/E ratio is 40.84. In terms of profitability, WAT's ROE is +0.39%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, WAT is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs TEM Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, TEM has a market cap of 11.5B. Regarding current trading prices, WAT is priced at $355.50, while TEM trades at $67.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas TEM's P/E ratio is -13.24. In terms of profitability, WAT's ROE is +0.39%, compared to TEM's ROE of -5.31%. Regarding short-term risk, WAT is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs QGEN Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, WAT is priced at $355.50, while QGEN trades at $48.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas QGEN's P/E ratio is 111.71. In terms of profitability, WAT's ROE is +0.39%, compared to QGEN's ROE of +0.03%. Regarding short-term risk, WAT is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs EXAS Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, EXAS has a market cap of 9.8B. Regarding current trading prices, WAT is priced at $355.50, while EXAS trades at $51.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas EXAS's P/E ratio is -9.37. In terms of profitability, WAT's ROE is +0.39%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, WAT is less volatile compared to EXAS. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs MEDP Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, MEDP has a market cap of 8.8B. Regarding current trading prices, WAT is priced at $355.50, while MEDP trades at $312.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas MEDP's P/E ratio is 23.44. In terms of profitability, WAT's ROE is +0.39%, compared to MEDP's ROE of +0.54%. Regarding short-term risk, WAT is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs CRL Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, CRL has a market cap of 7.4B. Regarding current trading prices, WAT is priced at $355.50, while CRL trades at $150.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas CRL's P/E ratio is -252.62. In terms of profitability, WAT's ROE is +0.39%, compared to CRL's ROE of -0.01%. Regarding short-term risk, WAT is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs GH Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, GH has a market cap of 6.2B. Regarding current trading prices, WAT is priced at $355.50, while GH trades at $49.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas GH's P/E ratio is -14.76. In terms of profitability, WAT's ROE is +0.39%, compared to GH's ROE of +3.69%. Regarding short-term risk, WAT is more volatile compared to GH. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs SYNH Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, WAT is priced at $355.50, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas SYNH's P/E ratio is 61.40. In terms of profitability, WAT's ROE is +0.39%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, WAT is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs RDNT Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, RDNT has a market cap of 4.4B. Regarding current trading prices, WAT is priced at $355.50, while RDNT trades at $57.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas RDNT's P/E ratio is -135.00. In terms of profitability, WAT's ROE is +0.39%, compared to RDNT's ROE of +0.03%. Regarding short-term risk, WAT is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs OLK Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, WAT is priced at $355.50, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas OLK's P/E ratio is -96.59. In terms of profitability, WAT's ROE is +0.39%, compared to OLK's ROE of -0.05%. Regarding short-term risk, WAT is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs SHC Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, SHC has a market cap of 3.2B. Regarding current trading prices, WAT is priced at $355.50, while SHC trades at $11.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas SHC's P/E ratio is 126.22. In terms of profitability, WAT's ROE is +0.39%, compared to SHC's ROE of +0.06%. Regarding short-term risk, WAT is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs TWST Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, TWST has a market cap of 2.2B. Regarding current trading prices, WAT is priced at $355.50, while TWST trades at $36.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas TWST's P/E ratio is -11.37. In terms of profitability, WAT's ROE is +0.39%, compared to TWST's ROE of -0.41%. Regarding short-term risk, WAT is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs GRAL Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, GRAL has a market cap of 1.8B. Regarding current trading prices, WAT is priced at $355.50, while GRAL trades at $48.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas GRAL's P/E ratio is -0.83. In terms of profitability, WAT's ROE is +0.39%, compared to GRAL's ROE of -0.75%. Regarding short-term risk, WAT is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs VIVO Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, WAT is priced at $355.50, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas VIVO's P/E ratio is 21.09. In terms of profitability, WAT's ROE is +0.39%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, WAT is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs CDNA Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, CDNA has a market cap of 1.1B. Regarding current trading prices, WAT is priced at $355.50, while CDNA trades at $19.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas CDNA's P/E ratio is 17.22. In terms of profitability, WAT's ROE is +0.39%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, WAT is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs OPK Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, OPK has a market cap of 1B. Regarding current trading prices, WAT is priced at $355.50, while OPK trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas OPK's P/E ratio is -22.00. In terms of profitability, WAT's ROE is +0.39%, compared to OPK's ROE of -0.03%. Regarding short-term risk, WAT and OPK have similar daily volatility (1.52).
WAT vs NEOG Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, NEOG has a market cap of 1B. Regarding current trading prices, WAT is priced at $355.50, while NEOG trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas NEOG's P/E ratio is -2.14. In terms of profitability, WAT's ROE is +0.39%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, WAT is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs FLGT Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, FLGT has a market cap of 596.7M. Regarding current trading prices, WAT is priced at $355.50, while FLGT trades at $19.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas FLGT's P/E ratio is -14.74. In terms of profitability, WAT's ROE is +0.39%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, WAT is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs GRALV Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, WAT is priced at $355.50, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas GRALV's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.39%, compared to GRALV's ROE of N/A. Regarding short-term risk, WAT is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs CSTL Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, CSTL has a market cap of 570.2M. Regarding current trading prices, WAT is priced at $355.50, while CSTL trades at $19.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas CSTL's P/E ratio is -103.95. In terms of profitability, WAT's ROE is +0.39%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, WAT is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs PSNL Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, PSNL has a market cap of 562.6M. Regarding current trading prices, WAT is priced at $355.50, while PSNL trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas PSNL's P/E ratio is -4.94. In terms of profitability, WAT's ROE is +0.39%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, WAT is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs MYGN Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, MYGN has a market cap of 491.3M. Regarding current trading prices, WAT is priced at $355.50, while MYGN trades at $5.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas MYGN's P/E ratio is -4.76. In terms of profitability, WAT's ROE is +0.39%, compared to MYGN's ROE of -0.14%. Regarding short-term risk, WAT is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs LAB Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, LAB has a market cap of 480.5M. Regarding current trading prices, WAT is priced at $355.50, while LAB trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas LAB's P/E ratio is -3.95. In terms of profitability, WAT's ROE is +0.39%, compared to LAB's ROE of -0.28%. Regarding short-term risk, WAT is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs CO Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, WAT is priced at $355.50, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas CO's P/E ratio is 5.06. In terms of profitability, WAT's ROE is +0.39%, compared to CO's ROE of +0.11%. Regarding short-term risk, WAT is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs FLDM Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, WAT is priced at $355.50, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas FLDM's P/E ratio is -4.74. In terms of profitability, WAT's ROE is +0.39%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, WAT is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs STIM Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, STIM has a market cap of 223.8M. Regarding current trading prices, WAT is priced at $355.50, while STIM trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas STIM's P/E ratio is -2.58. In terms of profitability, WAT's ROE is +0.39%, compared to STIM's ROE of -2.09%. Regarding short-term risk, WAT is more volatile compared to STIM. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs NEO Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, NEO has a market cap of 184.3M. Regarding current trading prices, WAT is priced at $355.50, while NEO trades at $7.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas NEO's P/E ratio is -11.74. In terms of profitability, WAT's ROE is +0.39%, compared to NEO's ROE of -0.09%. Regarding short-term risk, WAT is more volatile compared to NEO. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs ACRS Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, ACRS has a market cap of 167.8M. Regarding current trading prices, WAT is priced at $355.50, while ACRS trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas ACRS's P/E ratio is -0.97. In terms of profitability, WAT's ROE is +0.39%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, WAT is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs XGN Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, XGN has a market cap of 152.8M. Regarding current trading prices, WAT is priced at $355.50, while XGN trades at $6.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas XGN's P/E ratio is -8.32. In terms of profitability, WAT's ROE is +0.39%, compared to XGN's ROE of -1.34%. Regarding short-term risk, WAT is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs GTH Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, WAT is priced at $355.50, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas GTH's P/E ratio is -1.11. In terms of profitability, WAT's ROE is +0.39%, compared to GTH's ROE of -1.01%. Regarding short-term risk, WAT is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs PRENW Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, PRENW has a market cap of 118.7M. Regarding current trading prices, WAT is priced at $355.50, while PRENW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas PRENW's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.39%, compared to PRENW's ROE of -0.28%. Regarding short-term risk, WAT is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs ATLN Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, ATLN has a market cap of 118.4M. Regarding current trading prices, WAT is priced at $355.50, while ATLN trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas ATLN's P/E ratio is -0.55. In terms of profitability, WAT's ROE is +0.39%, compared to ATLN's ROE of -19.68%. Regarding short-term risk, WAT is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs PRE Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, PRE has a market cap of 117.3M. Regarding current trading prices, WAT is priced at $355.50, while PRE trades at $8.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas PRE's P/E ratio is -2.36. In terms of profitability, WAT's ROE is +0.39%, compared to PRE's ROE of -0.28%. Regarding short-term risk, WAT is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs GENE Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, WAT is priced at $355.50, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas GENE's P/E ratio is -38.25. In terms of profitability, WAT's ROE is +0.39%, compared to GENE's ROE of -3.62%. Regarding short-term risk, WAT is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs MDXH Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, MDXH has a market cap of 107.9M. Regarding current trading prices, WAT is priced at $355.50, while MDXH trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas MDXH's P/E ratio is -2.10. In terms of profitability, WAT's ROE is +0.39%, compared to MDXH's ROE of -5.35%. Regarding short-term risk, WAT is more volatile compared to MDXH. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs VNRX Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, VNRX has a market cap of 88.3M. Regarding current trading prices, WAT is priced at $355.50, while VNRX trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas VNRX's P/E ratio is -3.18. In terms of profitability, WAT's ROE is +0.39%, compared to VNRX's ROE of +1.08%. Regarding short-term risk, WAT is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs SERA Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, SERA has a market cap of 73M. Regarding current trading prices, WAT is priced at $355.50, while SERA trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas SERA's P/E ratio is -2.12. In terms of profitability, WAT's ROE is +0.39%, compared to SERA's ROE of -0.51%. Regarding short-term risk, WAT is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs NOTV Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, NOTV has a market cap of 63.2M. Regarding current trading prices, WAT is priced at $355.50, while NOTV trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas NOTV's P/E ratio is -0.59. In terms of profitability, WAT's ROE is +0.39%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, WAT is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs OPGN Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, OPGN has a market cap of 46.3M. Regarding current trading prices, WAT is priced at $355.50, while OPGN trades at $4.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas OPGN's P/E ratio is -0.30. In terms of profitability, WAT's ROE is +0.39%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, WAT is less volatile compared to OPGN. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs BDSX Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, BDSX has a market cap of 40.6M. Regarding current trading prices, WAT is priced at $355.50, while BDSX trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas BDSX's P/E ratio is -1.02. In terms of profitability, WAT's ROE is +0.39%, compared to BDSX's ROE of -1.68%. Regarding short-term risk, WAT is more volatile compared to BDSX. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs DRIO Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, DRIO has a market cap of 30.5M. Regarding current trading prices, WAT is priced at $355.50, while DRIO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas DRIO's P/E ratio is -1.25. In terms of profitability, WAT's ROE is +0.39%, compared to DRIO's ROE of -0.17%. Regarding short-term risk, WAT is more volatile compared to DRIO. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs STRRP Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, STRRP has a market cap of 29M. Regarding current trading prices, WAT is priced at $355.50, while STRRP trades at $8.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas STRRP's P/E ratio is -4.52. In terms of profitability, WAT's ROE is +0.39%, compared to STRRP's ROE of -0.24%. Regarding short-term risk, WAT is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs AKU Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, WAT is priced at $355.50, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas AKU's P/E ratio is -0.13. In terms of profitability, WAT's ROE is +0.39%, compared to AKU's ROE of -5.32%. Regarding short-term risk, WAT is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs PRPO Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, PRPO has a market cap of 16.8M. Regarding current trading prices, WAT is priced at $355.50, while PRPO trades at $11.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas PRPO's P/E ratio is -5.39. In terms of profitability, WAT's ROE is +0.39%, compared to PRPO's ROE of -0.26%. Regarding short-term risk, WAT is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs CEMI Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, WAT is priced at $355.50, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas CEMI's P/E ratio is -0.63. In terms of profitability, WAT's ROE is +0.39%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, WAT is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs ENZ Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, WAT is priced at $355.50, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas ENZ's P/E ratio is -2.24. In terms of profitability, WAT's ROE is +0.39%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, WAT is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs PMD Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, WAT is priced at $355.50, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas PMD's P/E ratio is -5.24. In terms of profitability, WAT's ROE is +0.39%, compared to PMD's ROE of -0.33%. Regarding short-term risk, WAT is less volatile compared to PMD. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs ADVB Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, ADVB has a market cap of 13.8M. Regarding current trading prices, WAT is priced at $355.50, while ADVB trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas ADVB's P/E ratio is -3.97. In terms of profitability, WAT's ROE is +0.39%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, WAT is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs ME Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, WAT is priced at $355.50, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas ME's P/E ratio is -0.03. In terms of profitability, WAT's ROE is +0.39%, compared to ME's ROE of -3.10%. Regarding short-term risk, WAT is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs TRIB Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, TRIB has a market cap of 12.6M. Regarding current trading prices, WAT is priced at $355.50, while TRIB trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas TRIB's P/E ratio is -0.38. In terms of profitability, WAT's ROE is +0.39%, compared to TRIB's ROE of +1.12%. Regarding short-term risk, WAT is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs INBS Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, INBS has a market cap of 11.7M. Regarding current trading prices, WAT is priced at $355.50, while INBS trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas INBS's P/E ratio is -1.27. In terms of profitability, WAT's ROE is +0.39%, compared to INBS's ROE of -1.72%. Regarding short-term risk, WAT is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs BNGO Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, BNGO has a market cap of 11.1M. Regarding current trading prices, WAT is priced at $355.50, while BNGO trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas BNGO's P/E ratio is -0.06. In terms of profitability, WAT's ROE is +0.39%, compared to BNGO's ROE of -1.57%. Regarding short-term risk, WAT is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs BIAFW Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, BIAFW has a market cap of 10.8M. Regarding current trading prices, WAT is priced at $355.50, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas BIAFW's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.39%, compared to BIAFW's ROE of -3.68%. Regarding short-term risk, WAT is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs BIAF Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, BIAF has a market cap of 10.2M. Regarding current trading prices, WAT is priced at $355.50, while BIAF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas BIAF's P/E ratio is -0.51. In terms of profitability, WAT's ROE is +0.39%, compared to BIAF's ROE of -3.68%. Regarding short-term risk, WAT is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs CNTG Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, WAT is priced at $355.50, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas CNTG's P/E ratio is -0.23. In terms of profitability, WAT's ROE is +0.39%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, WAT is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs STRR Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, STRR has a market cap of 6.2M. Regarding current trading prices, WAT is priced at $355.50, while STRR trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas STRR's P/E ratio is -0.65. In terms of profitability, WAT's ROE is +0.39%, compared to STRR's ROE of -0.24%. Regarding short-term risk, WAT is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs NVTA Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, WAT is priced at $355.50, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas NVTA's P/E ratio is -0.00. In terms of profitability, WAT's ROE is +0.39%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, WAT is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs MYNZ Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, MYNZ has a market cap of 5.3M. Regarding current trading prices, WAT is priced at $355.50, while MYNZ trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas MYNZ's P/E ratio is -0.07. In terms of profitability, WAT's ROE is +0.39%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, WAT is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs LMDX Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, WAT is priced at $355.50, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas LMDX's P/E ratio is -0.01. In terms of profitability, WAT's ROE is +0.39%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, WAT is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs LMDXW Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, WAT is priced at $355.50, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas LMDXW's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.39%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, WAT is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs BGLC Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, BGLC has a market cap of 4.9M. Regarding current trading prices, WAT is priced at $355.50, while BGLC trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas BGLC's P/E ratio is -2.28. In terms of profitability, WAT's ROE is +0.39%, compared to BGLC's ROE of -0.24%. Regarding short-term risk, WAT is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs CHEK Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, CHEK has a market cap of 4.4M. Regarding current trading prices, WAT is priced at $355.50, while CHEK trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas CHEK's P/E ratio is -0.36. In terms of profitability, WAT's ROE is +0.39%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, WAT is more volatile compared to CHEK. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs TTOO Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, TTOO has a market cap of 3.9M. Regarding current trading prices, WAT is priced at $355.50, while TTOO trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas TTOO's P/E ratio is -4.67. In terms of profitability, WAT's ROE is +0.39%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, WAT is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs BNR Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, BNR has a market cap of 3.6M. Regarding current trading prices, WAT is priced at $355.50, while BNR trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas BNR's P/E ratio is -1.04. In terms of profitability, WAT's ROE is +0.39%, compared to BNR's ROE of -0.39%. Regarding short-term risk, WAT is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs DMTK Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, WAT is priced at $355.50, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas DMTK's P/E ratio is -0.04. In terms of profitability, WAT's ROE is +0.39%, compared to DMTK's ROE of -0.80%. Regarding short-term risk, WAT is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs AWH Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, WAT is priced at $355.50, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas AWH's P/E ratio is -0.09. In terms of profitability, WAT's ROE is +0.39%, compared to AWH's ROE of +4.66%. Regarding short-term risk, WAT is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs NDRA Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, NDRA has a market cap of 2.7M. Regarding current trading prices, WAT is priced at $355.50, while NDRA trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas NDRA's P/E ratio is 0.01. In terms of profitability, WAT's ROE is +0.39%, compared to NDRA's ROE of -1.96%. Regarding short-term risk, WAT is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs SQL Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, WAT is priced at $355.50, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas SQL's P/E ratio is -0.40. In terms of profitability, WAT's ROE is +0.39%, compared to SQL's ROE of +10.89%. Regarding short-term risk, WAT is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs ISPC Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, ISPC has a market cap of 2.4M. Regarding current trading prices, WAT is priced at $355.50, while ISPC trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas ISPC's P/E ratio is -0.08. In terms of profitability, WAT's ROE is +0.39%, compared to ISPC's ROE of -2.85%. Regarding short-term risk, WAT is more volatile compared to ISPC. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs APDN Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, APDN has a market cap of 2.4M. Regarding current trading prices, WAT is priced at $355.50, while APDN trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas APDN's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.39%, compared to APDN's ROE of -2.81%. Regarding short-term risk, WAT is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs HTGM Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, WAT is priced at $355.50, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas HTGM's P/E ratio is -0.03. In terms of profitability, WAT's ROE is +0.39%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, WAT is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs BIOC Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, WAT is priced at $355.50, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas BIOC's P/E ratio is -0.01. In terms of profitability, WAT's ROE is +0.39%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, WAT is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs SQLLW Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, SQLLW has a market cap of 117.9K. Regarding current trading prices, WAT is priced at $355.50, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, WAT's ROE is +0.39%, compared to SQLLW's ROE of -19.68%. Regarding short-term risk, WAT is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.
WAT vs DHR-PA Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, WAT is priced at $355.50, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, WAT's ROE is +0.39%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, WAT is less volatile compared to DHR-PA. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs OCDX Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, WAT is priced at $355.50, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas OCDX's P/E ratio is -42.28. In terms of profitability, WAT's ROE is +0.39%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, WAT is less volatile compared to OCDX. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.
WAT vs MEUSW Comparison
WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WAT stands at 21.1B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, WAT is priced at $355.50, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WAT currently has a P/E ratio of 32.18, whereas MEUSW's P/E ratio is N/A. In terms of profitability, WAT's ROE is +0.39%, compared to MEUSW's ROE of -3.10%. Regarding short-term risk, WAT is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for WAT.